NCT06606730View on ClinicalTrials.gov

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

2,454

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

January 1, 2033

Study Completion Date

June 1, 2039

Conditions
Breast CancersTriple Negative Breast Cancer (TNBC)
Interventions
DRUG

Pembrolizumab

Administration of pembrolizumab for 6 months

OTHER

Deescalation

Patients will be followed up according to standard practice for 4 years

Trial Locations (2)

1200

RECRUITING

Cliniques Universitaires Saint Luc Brussels, Brussels

94805

RECRUITING

Institut Gustave Roussy, Villejuif

All Listed Sponsors
lead

UNICANCER

OTHER